La Haye
This article was originally published in The Tan Sheet
Executive Summary
Conducting Phase III clinical trials for an undisclosed dietary supplement ingredient to prevent macular degeneration and cataracts. Redmond, Washington-based La Haye said it plans to file an NDA for the product after the trials are completed, possibly within the next year. Testing began in 1989.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning